Patient |
Pathology | Grade | ER % | PGR % | HER 2+ | Ki-67 % | IHCH type | NAC type |
---|---|---|---|---|---|---|---|---|
1 | NST | 2 | 100 | 80 | 3 | 70 | Luminalny B HER 2+ | AT |
2a, b | NST | 2 | 100 | 50 | 0 | 30 | Luminalny B HER2− | AT and Taxotere |
3 | NST | 2 | 0 | 0 | 3 | 30 | HER 2+ | AT |
4 | NST | 2 | 90 | 85 | − | 2 | Luminalny A | AC and paklitaksel |
5 | NST | 1 | 100 | 80 | − | 2 | Luminalny A | Tamoksyfen |
6 | NST | 2 | 80 | 40 | 1 | 2 | Luminalny A | AC and paklitaksel |
7 | NST | 2 | 70 | 75 | 0 | 10 | Luminalny A | AC |
8 | NST | 2 | 100 | 40 | 1 | 15 | Luminalny A | AC |
9 | NST + CDIS | 2 | 90 | 40 | 1 | 30 | Luminalny B HER 2− | AC and paklitaksel |
10a, b, c | NST | 3 | 100 | 60 | − | 60 | Luminalny B HER 2− | AC and paklitaksel |
Patient |
Tumor size before treatment (W × D × L) in mm | Tumor size after treatment (W × D × L) in mm (Reduction in length compared to the initial result in %) RECIST 1.1 results | Tsukuba scale before/after treatment | Tumor size in final histopathological examination (mm) |
---|---|---|---|---|
1 | 8 × 10 × 9 | 4 × 3 × 3 (67%) PR | 2/4 | 4 × 5 × 5 |
2a | 19 × 27 × 17 | 12 × 7 × 8 (53%) PR | 4/2 | 25 × 22 × 20 |
2b | 35 × 41 × 36 | 9 × 9 × 6 (84%) PR | 4/2 | 35 × 45 × 25 |
3 | 25 × 27 × 26 | 6 × 6 × 7 (73%) PR | 4/3 | 40 × 30 × 20 |
4 | 20 × 23 × 25 | 10 × 8 × 12 (52%) PR | 2/2 | 25 × 17 × 25 |
5 | 9 × 20 × 13 | 6 × 13 × 4 (69%) PR | 5/5 | 22 × 17 × 18 |
6 | 22 × 13 × 21 | 18 × 20 × 11 (48%) PR | 4/4 | 35 × 17 × 12 |
7 | 25 × 17 × 15 | 14 × 6 × 11 (27%) SD | 4/2 | 13 × 12 × 11 |
8 | 30 × 21 × 41 | 20 × 16 × 34 (17%) SD | 4/4 | 30 × 30 × 41 |
9 | 10 × 24 × 16 | 10 × 14 × 9 (44%) PR | 2/2 | 0 |
10a | 17 × 10 × 21 | 5 × 5 × 8 (62%) PR | 3/4 | 9 × 7 × 11 |
10b | 3 × 10 × 8 | 2 × 8 × 6 (25%) SD | 3/3 | 0 |
10c | 5 × 5 × 4 |
|
2/2 |
0 |
Patient |
Reduction in cancer cells (%) | Classification of histopathology |
---|---|---|
1 | 100% | pCR |
2a, b | 60% | G3 |
3 | 85% | G3 |
4 | 30% | G3 |
5 | 0% | G1 |
6 | 0% | G1 |
7 | 91% | G4 |
8 | 0% | G1 |
9 | 100% | pCR |
10a | 95% | G4 |
10b | 100% | pCR |
10c | 100% | pCR |